Meeting
2019 ASCO Annual Meeting
DGM1 may serve as a novel genetic biomarker of response to enzastaurin in glioblastoma.
Authors
Nicholas A. Butowski
University of California, San Francisco, CA
Nicholas A. Butowski , Ronald L. Shazer , Hong Sun , Isabel Han , Manoj A. Jivani , Wen Luo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2023)
DOI
10.1200/JCO.2019.37.15_suppl.2023
Abstract #
2023
Poster Bd #
212
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma.
First Author: Howard Colman
Poster
2013 ASCO Annual Meeting
Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM).
First Author: Ryo Nishikawa
Poster
2023 ASCO Annual Meeting
Phase I and pharmacodynamic study of arsenic trioxide plus radiotherapy for newly diagnosed glioblastoma.
First Author: Samuel Ryu
Poster
2022 ASCO Annual Meeting
Phase 2 trial of bavituximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma.
First Author: Ina Ly